Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-108.91	-97.94	-257.83	-192.28	-178.3	-121.12
Depreciation & Amortization	3.61	4.25	7.13	8.45	8.2	7.69
Stock-Based Compensation	10.23	12.38	27.36	31.65	32.96	25.71
Other Adjustments	0.35	4.55	147.47	-1.24	-3.65	-0.67
Change in Receivables	9.97	0.4	2.76	2.34	-0.79	31.69
Changes in Accounts Payable	-3.02	-14.17	5.59	13.35	-7.66	10.7
Changes in Accrued Expenses	6.16	5.74	-12.69	0.94	0.37	6.88
Changes in Unearned Revenue	12.66	13.43	-161.16	-91.33	-84.2	216.55
Changes in Other Operating Activities	-10.63	-0.89	1.47	-7.61	-9.61	-13.23
Operating Cash Flow	-76.16	-67.14	-224.84	-223.63	-233.25	169.88
Capital Expenditures	-0.24	-0.27	-21.16	-20.17	-23.28	-14.71
Purchases of Investments	-	-	-59.55	-277.39	-338.16	-570.78
Proceeds from Sale of Investments	-	35.84	234.24	356.85	609.76	314.57
Other Investing Activities	1.48	1.95	-	-	-0.12	-0.7
Investing Cash Flow	1.24	37.52	153.53	59.29	248.2	-271.63
Issuance of Common Stock	65.99	29.28	16.04	86.76	36.12	153.87
Repurchase of Common Stock	-3.13	-0.9	-1.45	-2.1	-3.26	-0.77
Net Common Stock Issued (Repurchased)	62.85	28.38	14.59	84.66	32.86	153.1
Financing Cash Flow	62.94	28.38	14.59	84.66	32.86	153.1
Effect of Exchange Rate Changes on Cash and Cash Equivalents	1.8	-2.05	1.48	1.25	-0.26	-0.45
Net Cash Flow	-10.17	-3.29	-55.24	-78.43	47.54	50.9
Free Cash Flow	-76.4	-67.41	-246	-243.8	-256.53	155.16
FCF Margin	-232.38%	-116.62%	-139.59%	-219.05%	-231.73%	131.28%
Free Cash Flow Per Share	-0.31	-0.33	-1.41	-1.58	-1.77	1.15
Levered Free Cash Flow	-100.36	-89.84	-438.65	-288.65	-294.47	92.88
Unlevered Free Cash Flow	-100.04	-95.7	-449.54	-298.1	-299.84	83.95

Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q